Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Indirect comparison of bazedoxifene vs oral bisphosphonates for the prevention of vertebral fractures in postmenopausal osteoporotic women.

Ellis AG, Reginster JY, Luo X, Bushmakin AG, Williams R, Sutradhar S, Mirkin S, Jansen JP.

Curr Med Res Opin. 2014 Aug;30(8):1617-26. doi: 10.1185/03007995.2014.908279. Epub 2014 May 2. Review.

PMID:
24773456
2.

Bazedoxifene versus oral bisphosphonates for the prevention of nonvertebral fractures in postmenopausal women with osteoporosis at higher risk of fracture: a network meta-analysis.

Ellis AG, Reginster JY, Luo X, Cappelleri JC, Chines A, Sutradhar S, Jansen JP.

Value Health. 2014 Jun;17(4):424-32. doi: 10.1016/j.jval.2014.01.008. Epub 2014 May 5.

3.

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study.

Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N, Constantine GD, Adachi JD; Bazedoxifene Study Group.

Osteoporos Int. 2012 Jan;23(1):351-63. doi: 10.1007/s00198-011-1691-1. Epub 2011 Jul 21.

PMID:
21779819
4.

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2009 Jun;44(6):1049-54. doi: 10.1016/j.bone.2009.02.014. Epub 2009 Feb 28.

PMID:
19254788
5.
6.

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.

Osteoporos Int. 2010 Jun;21(6):1021-9. doi: 10.1007/s00198-009-1046-3. Epub 2009 Sep 1.

7.
8.

CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.

Albert SG, Reddy S.

Endocr Pract. 2017 Jul;23(7):841-856. doi: 10.4158/EP161678.RA. Epub 2017 Apr 27. Review.

PMID:
28448754
9.

Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.

Thomas T, Horlait S, Ringe JD, Abelson A, Gold DT, Atlan P, Lange JL.

Osteoporos Int. 2013 Jan;24(1):263-9. doi: 10.1007/s00198-012-2060-4. Epub 2012 Jun 27.

PMID:
22736069
10.

Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.

Zhang L, Pang Y, Shi Y, Xu M, Xu X, Zhang J, Ji L, Zhao D.

Menopause. 2015 Sep;22(9):1021-5. doi: 10.1097/GME.0000000000000466.

PMID:
25944523
11.

Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

Iwamoto J, Takeda T, Sato Y.

Curr Med Res Opin. 2006 May;22(5):919-28. Review.

PMID:
16709313
12.

Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.

Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D.

Appl Health Econ Health Policy. 2013 Oct;11(5):485-97. doi: 10.1007/s40258-013-0047-8.

PMID:
23868102
13.

Oral nitrogen-containing bisphosphonates: a systematic review of randomized clinical trials and vertebral fractures.

Bianchi G, Sambrook P.

Curr Med Res Opin. 2008 Sep;24(9):2669-77. doi: 10.1185/03007990802370912 . Epub 2008 Aug 8. Review.

PMID:
18694543
14.

Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies.

Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day BM, Barr C, Masanauskaite D.

Osteoporos Int. 2014 Jan;25(1):349-57. doi: 10.1007/s00198-013-2518-z. Epub 2013 Oct 18.

PMID:
24136103
15.

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C.

Osteoporos Int. 2013 Jan;24(1):209-17. doi: 10.1007/s00198-012-2068-9. Epub 2012 Jul 26.

16.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

17.

Medical treatment of vertebral osteoporosis.

Lippuner K.

Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.

18.

Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials.

Chen L, Wang G, Zheng F, Zhao H, Li H.

Osteoporos Int. 2015 Sep;26(9):2355-63. doi: 10.1007/s00198-015-3148-4. Epub 2015 May 6.

PMID:
25944731
19.

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

Kanis JA, Johansson H, Oden A, McCloskey EV.

Osteoporos Int. 2011 Aug;22(8):2347-55. doi: 10.1007/s00198-010-1474-0. Epub 2011 Feb 2. Erratum in: Osteoporos Int. 2011 Aug;22(8):2357-8.

PMID:
21287148
20.

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.

Murphy DR, Smolen LJ, Klein TM, Klein RW.

BMC Musculoskelet Disord. 2012 Oct 30;13:213. doi: 10.1186/1471-2474-13-213.

Supplemental Content

Support Center